BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations
DIPLOIDE is dedicated to utilizing genomics in order to advance precision medicine for cancer. DIPLOIDE’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
DIPLOIDE’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported (except for the Sentis Colorectal Cancer Panel for which a liquid biopsy version is still being developed).
DIPLOIDE’s Cancer+ Discovery Panel is designed to identify all classes of actionable genomic alterations, including SNP, CNV, InDels and Fusions, across a total of 508 cancer-related genes. Results are supported by in depth mutation analysis and pharmacogenomics information relating to 102 cancer therapeutics approved by the FDA or currently undergoing clinical trials.
Comprehensive: complete exome plus covered flanking intronic regions for all genes tested; A single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
Robust: Clinically important variants (pathogenic or likely pathogenic) are verified by Sanger sequencing, while qPCR verifies large genetic rearrangements.
Convenient: blood or saliva tests; DNA is also accepted.
Professional: the latest generation variant database guarantees up-to-date analysis and interpretation.